Mutual of America Capital Management LLC decreased its stake in shares of Encompass Health Co. (NYSE:EHC – Free Report) by 5.2% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 64,710 shares of the company’s stock after selling 3,584 shares during the quarter. Mutual of America Capital Management LLC owned about 0.06% of Encompass Health worth $6,254,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds also recently modified their holdings of the company. Magnetar Financial LLC grew its holdings in Encompass Health by 1,176.6% in the second quarter. Magnetar Financial LLC now owns 744,836 shares of the company’s stock worth $63,899,000 after purchasing an additional 814,018 shares during the period. Thrivent Financial for Lutherans grew its stake in shares of Encompass Health by 2,302.7% in the 2nd quarter. Thrivent Financial for Lutherans now owns 603,558 shares of the company’s stock valued at $51,780,000 after buying an additional 578,438 shares during the period. Price T Rowe Associates Inc. MD increased its position in Encompass Health by 614.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 540,519 shares of the company’s stock valued at $44,637,000 after buying an additional 464,897 shares in the last quarter. Epoch Investment Partners Inc. raised its stake in Encompass Health by 14.2% during the 1st quarter. Epoch Investment Partners Inc. now owns 1,598,042 shares of the company’s stock worth $131,966,000 after buying an additional 198,701 shares during the period. Finally, Vanguard Group Inc. boosted its holdings in Encompass Health by 1.7% in the first quarter. Vanguard Group Inc. now owns 10,166,147 shares of the company’s stock worth $839,520,000 after acquiring an additional 169,113 shares in the last quarter. Institutional investors own 97.25% of the company’s stock.
Encompass Health Trading Down 0.2 %
Shares of Encompass Health stock opened at $99.08 on Wednesday. The stock has a fifty day moving average price of $96.69 and a 200-day moving average price of $90.58. The company has a debt-to-equity ratio of 0.88, a current ratio of 1.04 and a quick ratio of 1.04. The firm has a market cap of $9.98 billion, a PE ratio of 23.93, a P/E/G ratio of 1.31 and a beta of 0.88. Encompass Health Co. has a 1 year low of $63.78 and a 1 year high of $104.55.
Encompass Health announced that its board has initiated a stock repurchase program on Wednesday, July 24th that authorizes the company to buyback $500.00 million in outstanding shares. This buyback authorization authorizes the company to reacquire up to 5.4% of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s board of directors believes its stock is undervalued.
Encompass Health Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, January 15th. Investors of record on Thursday, January 2nd will be paid a dividend of $0.17 per share. This represents a $0.68 dividend on an annualized basis and a dividend yield of 0.69%. The ex-dividend date is Thursday, January 2nd. Encompass Health’s payout ratio is currently 16.43%.
Wall Street Analyst Weigh In
A number of equities analysts have recently weighed in on the company. UBS Group upped their target price on Encompass Health from $100.00 to $110.00 and gave the stock a “buy” rating in a research report on Wednesday, September 25th. Stephens reaffirmed an “overweight” rating and issued a $105.00 price objective on shares of Encompass Health in a research note on Tuesday, August 6th. Truist Financial reissued a “buy” rating and set a $116.00 target price (up from $108.00) on shares of Encompass Health in a research report on Wednesday, October 30th. Barclays raised their price target on shares of Encompass Health from $109.00 to $116.00 and gave the company an “overweight” rating in a research report on Tuesday, October 29th. Finally, Royal Bank of Canada boosted their price objective on Encompass Health from $105.00 to $110.00 and gave the stock an “outperform” rating in a report on Wednesday, October 30th. Nine analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $107.11.
View Our Latest Analysis on EHC
Encompass Health Company Profile
Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.
Further Reading
- Five stocks we like better than Encompass Health
- How to Invest in Blue Chip Stocks
- Super Micro Computer Soars 28%: Is It Really Out of the Woods?
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Traders Are Flocking Back to Oil: What’s Fueling the Optimism
- Investing in Commodities: What Are They? How to Invest in Them
- 3 Hot Stock Trends to Ride Into 2025
Want to see what other hedge funds are holding EHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Encompass Health Co. (NYSE:EHC – Free Report).
Receive News & Ratings for Encompass Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Encompass Health and related companies with MarketBeat.com's FREE daily email newsletter.